Introduction
============

Digestive system cancers, one of the most common malignancies, have overtaken cardiovascular disease and infectious diseases as a major cause of morbidity and mortality in the world.[@b1-ott-11-1229]--[@b3-ott-11-1229] They cause approximately 2.9 million deaths per year.[@b4-ott-11-1229] Although novel targeted therapies for terminal cancer patients are emerging, the application range is still limited.[@b5-ott-11-1229] Therefore, it is of great importance to identify applicable prognostic biomarkers to improve the unfavorable prognosis.

Xenopus kinesin-like protein 2 (TPX2), a 100 kDa protein, was first described by Heidebrecht et al in 1997.[@b6-ott-11-1229] Human TPX2, a microtubule-associated protein located in chromosome 20q11.2,[@b7-ott-11-1229],[@b8-ott-11-1229] was reported to play an important role in spindle assembly and dynamics.[@b9-ott-11-1229],[@b10-ott-11-1229] In addition, TPX2 was found to participate in the regulation of cell mitosis or meiosis.[@b11-ott-11-1229],[@b12-ott-11-1229] Overexpression of TPX2 could cause DNA aneuploidy and polyploidy.[@b13-ott-11-1229],[@b14-ott-11-1229] The aberrant expression of TPX2 could inhibit normal mitosis and lead to carcinogenesis. Thus, TPX2 expression might have great potential for a more precise evaluation of progression of malignancy.

Among numerous independent studies, the clinical predictive value of TPX2 in patients with cancer, especially digestive system cancer, remains controversial. A recently published work by Liu et al revealed a significant relationship of positive TPX2 to cancer stage III/IV and cancer grade of differentiation.[@b15-ott-11-1229] Huang et al also showed that TPX2 level was positively associated with (TNM) tumor stage and Edmondson-Steiner grading.[@b16-ott-11-1229] In obvious contrast, TPX2 expression was not correlated with TNM stage, cancer grade of differentiation, and tumor capsule according to the study by Liang et al.[@b17-ott-11-1229] No correlation between TPX2 expression and tumor staging, grading, or TNM stage was indicated.[@b18-ott-11-1229]

The conflicting results lead to an unresolved issue on the relationship of TPX2 expression with clinical outcomes of cancer patients. Therefore, we performed the meta-analysis to evaluate the association of TPX2 expression with disease-free survival (DFS), overall survival (OS), and clinicopathological features of digestive system cancers.

Methods
=======

Literature search strategy
--------------------------

The meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement and guidelines.[@b19-ott-11-1229] Details of the preferred reporting items for systematic reviews and meta-analyses statement criteria used are available in [Table S1](#SD4-ott-11-1229){ref-type="supplementary-material"}. A comprehensive literature search from electronic databases PubMed, EMBASE, Cochrane library, CBM, and Chinese CNKI was performed (up to July 2016). Search keywords were ("TPX2" or "Xklp2" or "Xenopus kinesin-like protein 2") and ("tumor" or "malignancy" or "neoplasia" or "cancer" or "carcinoma") and "prognosis" or "survival" or "outcome" or "mortality". Reference lists in the included studies were also searched manually to identify potential studies.

Selection criteria
------------------

### Inclusion criteria

1.  Cohort studies and case-control studies.

2.  Studies investigating any type of digestive system cancers.

3.  Studies providing data for the estimation of the hazard ratio (HR) for OS or DFS with 95% confidence intervals (CIs) included.

4.  Studies where the association between TPX2 and clinical prognosis was clarified.

5.  Studies of TPX2 overexpression based on primary cancer tissues.

6.  The most samples and most informative studies when the duplicate studies were published.

### Exclusion criteria

1.  Studies irrelevant to digestive system cancers.

2.  Studies which assessed patients with metastatic cancers other than primary cancer.

3.  Data that were incomplete or could not be combined.

4.  Case reports, comments, letters, meeting abstract, systematic reviews, and meta-analysis.

Data extraction
---------------

Data extraction tables were set up to enter data from each study, including first author, publication year, country of origin, type of tumor, TNM stage, number of patients recruited, cut-off value, TPX2 expression and detection method, preoperative treatment, outcome measures, follow-up time, survival analysis, and HRs with the corresponding 95% CIs ([Table 1](#t1-ott-11-1229){ref-type="table"}). Two authors (QW and GW) independently assessed the quality of the studies, and a consensus decision was made regarding any discrepancies by a third investigator (XLH).

Under the condition that the total number of events and the corresponding *p*-values were not reported in text, several survival rates at specified times from Kaplan--Meier survival curves were extracted using the Engauge Digitizer version 4.1. The extracted survival rates at specified times were input into the calculation spreadsheet developed by Tierney et al[@b20-ott-11-1229] to reconstruct the survival curve and produce the HRs with their 95% CIs.

Quality assessment
------------------

Study quality in this meta-analysis was assessed using the Quality Scale for Biological Prognostic Factors reported previously.[@b21-ott-11-1229] QW and GW independently assessed the quality of each study according to the quality scale ([Table S2](#SD5-ott-11-1229){ref-type="supplementary-material"}).[@b21-ott-11-1229] The quality scale was focused on four aspects: scientific design, laboratory methodology, generalizability, and result analysis. The overall maximum points were 40. The global scores were presented as percentages, ranging from 0% to 100%. Studies with higher proportion values were considered high quality. Any discrepancies on the eligibility of studies were resolved by a third reviewer (XLH) until the two original reviewers reached consensus.

Statistical analysis
--------------------

Statistical analysis was performed by STATA version 12.1 (StataCorp LP, College Station, TX, USA). Heterogeneity was detected using the *I*^2^ statistic (25%, 50%, and 75% indicated low, moderate, and high heterogeneity, respectively). In this analysis, *I*^2^\<50% indicated low heterogeneity, and *I*^2^\>50% indicated substantial heterogeneity. Both fixed- and random-effect models were assessed for the pooled estimates. Furthermore, cumulative meta-analysis was performed to show the trend in the estimated effect. Subgroup analyses were carried out on cancer type, sample size, quality score, and laboratory detection method. Sensitivity analysis was carried out by sequentially omitting individual study to guarantee the stability of the results. The odds ratios (ORs) with corresponding 95% CIs were used to assess the correlation between TPX2 expression and clinicopathological features. Egger's regression plot and Begg's test were used to evaluate the risk of publication bias.

Results
=======

Study characteristics
---------------------

The search strategy retrieved 174 potentially relevant studies. According to the inclusive criteria, 10 eligible studies with a total of 906 patients, conducted in two countries (nine in China and one in Japan), were included in this meta-analysis.[@b15-ott-11-1229]--[@b18-ott-11-1229],[@b22-ott-11-1229]--[@b27-ott-11-1229] The flowchart of study selection is shown in [Figure 1](#f1-ott-11-1229){ref-type="fig"}. Study characteristics of these studies are summarized in [Table 1](#t1-ott-11-1229){ref-type="table"}. Among the studies included, five focused on hepatocellular carcinoma (HCC), and two were about esophageal squamous cell carcinoma (ESCC), with single studies about gastric cancer, pancreatic cancer, and colon cancer. There were seven studies for DFS, five for OS, and one for recurrence-free survival (RFS). Expression of TPX2 was evaluated by immunocytochemistry (IHC) in seven studies, and reverse transcription polymerase chain reaction (RT-PCR) was adopted in the remaining three studies. The total positive rate of TPX2 was 63.7% (from 47% to 90.6%). The maximum and minimum sample sizes were 203 and 19, respectively. The quality assessment of the included studies is shown in [Table 2](#t2-ott-11-1229){ref-type="table"}.

Aberrant overexpression of TPX2 in digestive system cancers
-----------------------------------------------------------

Meta-analysis using a random-effects model indicated that TPX2 was highly expressed in digestive system cancers, including liver cancer (pooled HR =6.29, 95% CI: 4.50--8.81), esophageal cancer (pooled HR =6.35, 95% CI: 1.48--27.3), gastric cancer (pooled HR =3.74, 95% CI: 2.07--6.76), and colon cancer (pooled HR =78.09, 95% CI: 27.90--218.56) ([Figure 2](#f2-ott-11-1229){ref-type="fig"}).

Prognostic value of TPX2 for DFS of digestive system cancers
------------------------------------------------------------

Among the studies included, a total of seven with 725 subjects reported HRs for DFS. As shown in [Figure 3](#f3-ott-11-1229){ref-type="fig"}, it was indicated that elevated TPX2 expression predicted a poor outcome for DFS of digestive system cancer patients (pooled HR =2.48, 95% CI: 1.96--3.13). In addition, a cumulative meta-analysis according to the time of publication was carried out. A stable trend of significant correlation between TPX2 overexpression and a poor DFS was confirmed as time accumulates with an increasingly narrow 95% CI ([Figure S1](#SD1-ott-11-1229){ref-type="supplementary-material"}). Although no inter-study heterogeneity was observed in the quantitative synthesis (*I*^2^=0.0%, *p*=0.903), subsequent analyses of subgroups were performed on the basis of cancer type (liver, esophageal, gastric, colon, and pancreatic), sample size (≥100 vs \<100), quality score (≥85% vs \<85%), and laboratory detection method (RT-PCR vs IHC) ([Figure 4](#f4-ott-11-1229){ref-type="fig"}). A significant correlation between TPX2 overexpression and a poor DFS was shown in patients with liver cancer (HR =2.57, 95% CI: 1.82--3.64), esophageal cancer (HR =2.10, 95% CI: 1.19--3.71), gastric cancer (HR =2.17, 95% CI: 1.23--3.83), colon cancer (HR =3.70, 95% CI: 1.70--8.05), and pancreatic cancer (HR =2.42, 95% CI: 1.27--4.61), indicating the expression level of TPX2 could be used to predict the DFS of various kinds of digestive system malignancies. In the analysis stratified by the size of the sample, TPX2 was found to be significantly associated with DFS of patients in studies with sample size \>100 (HR =2.64, 95% CI: 1.91--3.66) and sample size \<100 (HR =2.32, 95% CI: 1.66--3.23). There was a significant association of increased TPX2 expression with DFS of patients in studies with a quality score of \>85% (HR =2.54, 95% CI: 1.81--3.57) and \<85% (HR =2.42, 95% CI: 1.76--3.33). Stratified analysis on the laboratory detection method revealed a significant relationship of elevated TPX2 to DFS of patients in both RT-PCR subgroup (HR =2.66, 95% CI: 1.53--4.62) and IHC subgroup (HR =2.44, 95% CI: 1.89--3.15). In order to evaluate the robustness of the pooled results, we conducted sensitivity analysis by sequentially omitting one study. The leave-one-out sensitivity analysis implied that no individual study altered the pooled estimates significantly ([Figure 5A](#f5-ott-11-1229){ref-type="fig"}), validating the stability of our results.

Prognostic value of TPX2 for OS and RFS of digestive system cancers
-------------------------------------------------------------------

Five studies comprising 630 individuals reported OS according to the expression level of TPX2, and one study consisting of 100 patients reported HRs and corresponding 95% CIs for RFS. As shown in [Figure 3](#f3-ott-11-1229){ref-type="fig"}, upregulated TPX2 expression was tightly associated with poor clinical outcome for OS (pooled HR =2.66, 95% CI: 2.04--3.48) of digestive system tumors. We also conducted sensitivity analysis by sequentially omitting one study. The results showed that no individual study altered the pooled estimates significantly ([Figure 5B](#f5-ott-11-1229){ref-type="fig"}), validating the stability of our results. In addition, a cumulative meta-analysis according to the time of publication was carried out. A stable trend of significant correlation between TPX2 overexpression and a poor OS was confirmed as time accumulates with an increasingly narrow 95% CI ([Figure S2](#SD2-ott-11-1229){ref-type="supplementary-material"}). Similarly, TPX2 overexpression was associated with a poor RFS (HR =3.12, 95% CI: 1.52--4.56) in patients with HCC.

Independent prognostic value of TPX2 in digestive system cancers
----------------------------------------------------------------

Cox multivariate analyses were performed in five studies, and the role of TPX2 as an independent predictive factor for OS of patients with digestive system cancer was investigated. The pooled results showed that TPX2 expression was an independent prognostic factor for OS of patients with digestive system cancers (pooled HR =2.31, 95% CI: 1.78--3.01), and there was no heterogeneity among the studies (*I*^2^=0.0%, *p*=0.660) ([Figure 6](#f6-ott-11-1229){ref-type="fig"}).

Association between TPX2 and clinicopathological characteristics of digestive system cancers
--------------------------------------------------------------------------------------------

A total of eight studies assessed the relationship between TPX2 expression and clinicopathological characteristics of digestive system cancers, including five about HCC, and three studies about ESCC, gastric cancer, and colorectal cancer, respectively. The pooled estimates showed that TPX2 expression was closely correlated with pathological grade (pooled HR =3.438, 95% CI: 2.040--5.794) and TNM stage (pooled HR =2.690, 95% CI: 1.540--4.699) in HCC, but was not related to most of the clinicopathological features, including age, gender, tumor size, hepatitis B surface antigen (HBsAg) status, alpha-fetoprotein (AFP), liver cirrhosis, tumor number, tumor encapsulation, and vascular invasion. A significant relationship between TPX2 expression and lymph node metastasis (pooled HR =2.341, 95% CI: 1.478--3.709), distant metastasis (pooled HR =3.964, 95% CI: 1.987--7.906), and TNM stage (pooled HR =2.515, 95% CI: 1.332--4.746) was observed in three other cancers, including ESCC, gastric cancer (GC), and colorectal cancer. As shown in [Table 3](#t3-ott-11-1229){ref-type="table"}, there was no statistically significant publication bias across all the groups.

Publication bias
----------------

Egger's regression plot and Begg's test were performed to assess the potential bias in the available literature. Egger's test revealed no evidence of potential publication bias for DFS (*p*=0.232) and OS (*p*=0.785). In addition, Begg's test also indicated that there was no potential publication bias for DFS (*p*=0.23) and OS (1.000) ([Figure S3](#SD3-ott-11-1229){ref-type="supplementary-material"}).

Discussion
==========

This study explored the prognostic role of TPX2, an important regulatory molecule involved in spindle assembly and dynamics, in various types of digestive system malignancies. We used a comprehensive and detailed search strategy combined with predetermined inclusion and exclusion criteria, providing convincing evidence that the expression level of TPX2 is predictive of poor survival in digestive system cancers.

In total, 10 studies comprising 906 patients were included in the meta-analysis. Our pooled results showed that TPX2 might be utilized as an unfavorable and negative prognostic marker for digestive system cancer. We found that TPX2 overexpression is negatively correlated with OS, DFS, and RFS in patients with digestive system cancer. Moreover, the result of cumulative meta-analysis confirmed the stable trend of significant association between TPX2 and DFS and OS as time-accumulated. Stratified analyses were performed, and significant results pertaining to the relationship of TPX2 to a poor DFS were yielded in all subgroups on the basis of cancer type, sample size, quality of study, and laboratory detection method. Next, sensitivity analysis showed that no single study altered the pooled estimates significantly. Furthermore, the pooled results showed that TPX2 expression was an independent prognostic factor for DFS of patients with digestive system cancers. In addition, TPX2 expression was closely correlated with pathological grade and TNM stage in HCC. A significant relationship between TPX2 expression and lymph node metastasis, distant metastasis, and TNM stage was observed in ESCC, GC, and colorectal cancer. Besides, no statistically significant inter-study heterogeneity was found in our meta-analysis.

In addition to gastrointestinal cancer, TPX2 has also been reported to be highly expressed in other non-gastrointestinal cancers, such as bladder cancer,[@b28-ott-11-1229] brain cancer,[@b29-ott-11-1229] lung cancer,[@b30-ott-11-1229],[@b31-ott-11-1229] oral cancer,[@b32-ott-11-1229] ovarian cancer,[@b33-ott-11-1229] and salivary gland cancer.[@b34-ott-11-1229] However, the mechanism by which TPX2 promotes cancer progression has not been fully elucidated so far. Martens-de Kemp et al[@b35-ott-11-1229] identified 71 target genes by genome-wide siRNA screens, in which TPX2 was shown to be essential for tumor cell survival. Furthermore, in vivo and in vitro, silencing of *TPX2* gene could reduce the tumorigenicity of cancer cells.[@b26-ott-11-1229] Liu et al[@b15-ott-11-1229] found that TPX2 could upregulate the expression of matrix metalloproteases2 (MMP2) by activation of the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway in HCC. In addition to PI3K/Akt signaling pathway, TPX2 may partially activate the Ras/Raf/MEK/ERK signaling pathway to promote tumor proliferation.[@b26-ott-11-1229] It has been known previously that the upregulation of TPX2 in cancer cells can promote epithelial-to-mesenchymal transition (EMT) by regulating the expression of EMT-related proteins. Depletion of TPX2 can lead to the upregulation of E-cadherin proteins that inhibit tumor metastasis and the downregulation of N-cadherin, β-catenin, Slug, MMP-9 and MMP-2 proteins that promote tumor metastasis.[@b26-ott-11-1229] Moreover, TPX2 plays an important role in regulating cell cycle and proliferation. Wei et al found that silencing TPX2 through siRNA transfection significantly inhibited the cell cycle progression at G1 arrest.[@b26-ott-11-1229] Collectively, previous studies indicate that TPX2 overexpression is associated with a tumor's proliferation, apoptosis, EMT, and invasiveness. However, further research is still needed.

The identification of prognostic factors is critical to distinguish high-risk patients who are good candidates for individualized treatment. Our findings suggested that TPX2 might potentially act as a clinical biomarker, and might also be a molecular target for cancer therapy. Recently, Kilchmann et al[@b36-ott-11-1229] reported the discovery of a selective inhibitor of Aurora A. The inhibitor locks Aurora A in an inactive conformation and disrupts the function of TPX2. Chowdhury et al[@b37-ott-11-1229] discovered that TPX2 might serve as a biomarker for identifying a subpopulation of patients who are sensitive to Aurora A-inhibitor treatment. Therefore, increasing studies will focus on TPX2 as a novel antitumor therapeutic approach in the future.

There were some limitations in our meta-analysis. First, all of the included patients were Asian, decreasing the applicability of the results across different ethnicities. Therefore, additional well-designed studies with patients of different ethnic backgrounds are highly needed to give more reliable results. Second, the cutoff value of TPX2 expression varied across different studies and a consensus value was rather difficult to reach. Third, in some studies, estimated HRs with corresponding 95% CIs were calculated by Kaplan--Meier survival curves. Fourth, the number of studies enrolled in our analysis was relatively small. Finally, biological subtypes of a given tumor were not assessed because the distinction between different subtypes was not available for most of the studies.

Conclusion
==========

In conclusion, this meta-analysis showed that TPX2 might be an independent prognostic factor for survival of patients with digestive system cancer. Furthermore, TPX2 expression might be associated with TNM stage and pathological grade in digestive system cancer. Additional well-designed studies with larger and more diverse populations are highly needed to validate our current data.

Supplementary materials
=======================

###### 

Cumulative meta-analysis of the correlation between TPX2 overexpression and DFS according to the time of publication.

**Abbreviations:** TPX2, Xenopus kinesin-like protein 2; HR, hazard ratio; CI, confidence interval.

###### 

Cumulative meta-analysis of the correlation between TPX2 overexpression and OS according to the time of publication.

**Abbreviations:** TPX2, Xenopus kinesin-like protein 2; OS, overall survival; HR, hazard ratio; CI, confidence interval.

###### 

Funnel plot for publication bias of studies for DFS (**A**) and OS (**B**).

**Abbreviations:** DFS, disease-free survival; OS, overall survival; HR, hazard ratio.

###### 

PRISMA 2009 checklist

  Section/topic                        \#   Checklist item                                                                                                                                                                                                                                                                                                Reported on page \#
  ------------------------------------ ---- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------
  **Title**                                                                                                                                                                                                                                                                                                                                               
  Title                                1    Identify the report as a systematic review, meta-analysis, or both.                                                                                                                                                                                                                                           1
  **Abstract**                                                                                                                                                                                                                                                                                                                                            
  Structured summary                   2    Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.   2
  **Introduction**                                                                                                                                                                                                                                                                                                                                        
  Rationale                            3    Describe the rationale for the review in the context of what is already known.                                                                                                                                                                                                                                3\~4
  Objectives                           4    Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).                                                                                                                                                    3\~4
  **Methods**                                                                                                                                                                                                                                                                                                                                             
  Protocol and registration            5    Indicate if a review protocol exists, if and where it can be accessed (eg, web address), and, if available, provide registration information including registration number.                                                                                                                                   NA
  Eligibility criteria                 6    Specify study characteristics (eg, PICOS, length of follow-up) and report characteristics (eg, years considered, language, publication status) used as criteria for eligibility, giving rationale.                                                                                                            4--5
  Information sources                  7    Describe all information sources (eg, databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.                                                                                                                                      4
  Search                               8    Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.                                                                                                                                                                                 4
  Study selection                      9    State the process for selecting studies (ie, screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).                                                                                                                                                       4
  Data collection process              10   Describe the method of data extraction from reports (eg, piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.                                                                                                                                  5
  Data items                           11   List and define all variables for which data were sought (eg, PICOS, funding sources) and any assumptions and simplifications made.                                                                                                                                                                           5
  Risk of bias in individual studies   12   Describe the methods used for assessing the risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.                                                                                6
  Summary measures                     13   State the principal summary measures (eg, risk ratio, difference in means).                                                                                                                                                                                                                                   7
  Synthesis of results                 14   Describe the methods of handling data and combining results of studies, if done, including measures of consistency (eg, *I*^2^) for each meta-analysis.                                                                                                                                                       6

**Abbreviations:** PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; NA, not available.

###### 

Quality assessment of the included studies based on the quality scale for biological prognostic factors

  Study                                  Scientific design   Laboratory methodology   Generalizability   Results analysis   Global score (%)
  -------------------------------------- ------------------- ------------------------ ------------------ ------------------ ------------------
  Liu et al (2015)[@b38-ott-11-1229]     9                   11                       10                 7                  93
  Huang et al (2014)[@b39-ott-11-1229]   8                   8                        10                 6                  80
  Liang et al (2015)[@b40-ott-11-1229]   8                   11                       10                 7                  90
  Satow et al (2010)[@b41-ott-11-1229]   8                   10                       9                  2                  73
  Liang et al (2015)[@b42-ott-11-1229]   9                   11                       10                 4                  85
  Liang et al (2016)[@b43-ott-11-1229]   9                   10                       9                  6                  85
  Hsu et al (2014)[@b44-ott-11-1229]     8                   10                       10                 4                  80
  Liu et al (2013)[@b45-ott-11-1229]     8                   9                        8                  2                  68
  Wei et al (2013)[@b46-ott-11-1229]     9                   10                       9                  4                  80
  Zhang et al (2012)[@b47-ott-11-1229]   8                   9                        8                  4                  73
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![Flowchart of the process of identifying relevant studies.\
**Abbreviation:** TPX2, Xenopus kinesin-like protein 2.](ott-11-1229Fig1){#f1-ott-11-1229}

![Meta-analysis of aberrant overexpression of TPX2 in digestive system cancers.\
**Note:** Weights are from random-effects analysis.\
**Abbreviations:** TPX2, Xenopus kinesin-like protein 2; OR, odds ratios; CI, confidence interval.](ott-11-1229Fig2){#f2-ott-11-1229}

![Meta-analysis of the pooled HRs of patients with elevated TPX2 expression.\
**Note:** Weights are from random-effects analysis.\
**Abbreviations:** TPX2, Xenopus kinesin-like protein 2; HR, hazard ratio; CI, confidence interval; DFS, disease-free survival; OS, overall survival.](ott-11-1229Fig3){#f3-ott-11-1229}

![Subgroup analyses were performed by the factors of cancer type (**A**), sample size (**B**), quality score (**C**), and laboratory detection method (**D**).\
**Note:** Weights are from random-effects analysis.\
**Abbreviations:** HR, hazard ratio; CI, confidence interval.](ott-11-1229Fig4){#f4-ott-11-1229}

![Sensitivity analysis of the effect of the individual study on the pooled HRs for the correlation between TPX2 and disease-free survival (**A**) and overall survival (**B**) in patients with digestive system cancer.\
**Abbreviations:** TPX2, Xenopus kinesin-like protein 2; HR, hazard ratio; CI, confidence interval.](ott-11-1229Fig5){#f5-ott-11-1229}

![Meta-analysis of the independent role of TPX2 in overall survival of cancer patients.\
**Note:** Weights are from random-effects analysis.\
**Abbreviations:** TPX2, Xenopus kinesin-like protein 2; HR, hazard ratio; CI, confidence interval.](ott-11-1229Fig6){#f6-ott-11-1229}

###### 

Characteristics of the studies included in the meta-analysis (n=10)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author                    Year   Country   Tumor type   Sample         Tumor stage   Sample size   Cutoff value                 Elevated TPX2 (n, %)   Laboratory method   PT   Sample storage   Outcome measures       Follow-up time (months)   Survival analysis          HR (95% CI)
  ------------------------------- ------ --------- ------------ -------------- ------------- ------------- ---------------------------- ---------------------- ------------------- ---- ---------------- ---------------------- ------------------------- -------------------------- -------------------------
  Liang et al[@b23-ott-11-1229]   2016   China     GC           Tumor tissue   I--IV         115           Score ≥2                     54, 47                 IHC                 NA   Frozen           OS                     48                        Univariate                 OS: 2.84 (1.34--5.98)

  Hsu et al[@b24-ott-11-1229]     2014   China     ESCC         Tumor tissue   I--IV         96            Score ≥2                     87, 90.6               IHC                 NA   Frozen           OS, DFS                96                        Univariate                 OS: 1.9 (1.04--3.48)\
                                                                                                                                                                                                                                                                                     DFS: 2.1 (1.19--3.71)

  Liu et al[@b25-ott-11-1229]     2013   China     ESCC         Tumor tissue   NA            62            Nuclear staining above 10%   69, 74.1               IHC                 No   FFPE             Lymphatic metastasis   NA                        NA                         NA

  Wei et al[@b26-ott-11-1229]     2013   China     CRC          Tumor tissue   I--IV         203           Score ≥3                     124, 61.0              IHC                 No   FFPE             OS                     100                       Univariate, multivariate   OS: 2.2 (1.2--3.9)

  Liu et al[@b15-ott-11-1229]     2015   China     HCC          Tumor tissue   I--III        130           Score ≥2                     96, 74.1               IHC                 No   Frozen           OS, DFS                100                       Univariate, multivariate   OS: 2.58 (1.52--4.37)\
                                                                                                                                                                                                                                                                                     DFS: 2.67 (1.68--4.23)

  Huang et al[@b16-ott-11-1229]   2014   China     HCC          Tumor tissue   I--IV         86            Nuclear staining above 10%   56, 65.1               IHC                 No   NA               OS, DFS                60                        Univariate, multivariate   OS: 3.7 (1.7--8.1)\
                                                                                                                                                                                                                                                                                     DFS: 2.2 (1.2--3.9)

  Liang et al[@b18-ott-11-1229]   2015   China     HCC          Tumor tissue   I--IV         50            Nuclear staining above 10%   28, 56.0               RT-PCR              NA   FFPE             DFS                    42                        Univariate                 DFS: 3.45 (1.18--10.07)

  Satow et al[@b22-ott-11-1229]   2010   Japan     HCC          Tumor tissue   NA            19            Nuclear staining above 10%   11, 57.8               RT-PCR              NA   FFPE             Metastasis             NA                        NA                         NA

  Liang et al[@b17-ott-11-1229]   2015   China     HCC          Tumor tissue   I--IV         100           Score ≥2                     66, 66.0               IHC                 No   Frozen           RFS                    48                        Univariate                 RFS: 3.12 (1.52--4.56)

  Zhang et al[@b27-ott-11-1229]   2012   China     PDA          Tumor tissue   I--IV         45            Score ≥2                     25, 55.5               RT-PCR              NA   Frozen           DFS                    60                        Univariate, multivariate   DFS: 2.42 (1.27--4.61)
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** CI, confidence interval; DFS, disease-free survival; ESCC, esophageal squamous cell carcinoma; GC, gastric cancer; HCC, hepatocellular carcinoma; HR, hazard ratio; IHC, immunocytochemistry; FFPE, formalin-fixed paraffin-embedded; PDA, pancreatic ductal adenocarcinoma; NA, not available; OS, overall survival; PT, preoperative treatment; RFS, recurrence-free survival; TPX2, Xenopus kinesin-like protein 2.

###### 

Quality assessment of the included studies based on the quality scale for biological prognostic factors

  Study                                  Scientific design   Laboratory methodology   Generalizability   Results analysis   Global score (%)
  -------------------------------------- ------------------- ------------------------ ------------------ ------------------ ------------------
  Liu et al (2015)[@b15-ott-11-1229]     9                   11                       10                 7                  93
  Huang et al (2014)[@b16-ott-11-1229]   8                   8                        10                 6                  80
  Liang et al (2015)[@b18-ott-11-1229]   8                   11                       10                 7                  90
  Satow et al (2010)[@b22-ott-11-1229]   8                   10                       9                  2                  73
  Liang et al (2015)[@b17-ott-11-1229]   9                   11                       10                 4                  85
  Liang et al (2016)[@b23-ott-11-1229]   9                   10                       9                  6                  85
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###### 

Results of meta-analysis of increased TPX2 expression and clinicopathological features of three types of cancer

  Clinicopathological features                             No of studies   No of patients   Fixed-effects model    Random-effects model   Heterogeneity          Begg's test   Egger's test                                      
  -------------------------------------------------------- --------------- ---------------- ---------------------- ---------------------- ---------------------- ------------- -------------- ------- -------- ------- --------- -------
  **HCC**                                                                                                                                                                                                                        
  Age (\>45 vs ≤45) (years)                                3               286              1.366 (0.800--2.334)   0.253                  1.266 (0.571--2.807)   0.561         46.9%          0.152   --1.57   0.296   --2.32    0.259
  Gender (male vs female)                                  3               286              0.719 (0.393--1.315)   0.809                  0.719 (0.392--1.317)   0.285         0.0%           0.809   1.57     0.296   0.247     0.247
  Tumor size (\>5 cm vs ≤5 cm)                             3               286              0.804 (0.476--1.355)   0.412                  0.758 (0.390--1.474)   0.414         28.5%          0.247   --1.57   0.296   --2.76    0.222
  Pathological grade (III--IV vs I--II)                    3               286              3.440 (2.042--5.796)   \<**0.001**            3.438 (2.040--5.794)   \<**0.001**   0.0%           0.900   --0.52   1.000   --1.32    0.412
  HBsAg status (positive vs negative)                      3               286              1.396 (0.785--2.483)   0.256                  1.391 (0.778--2.486)   0.266         0.0%           0.656   --0.52   1.000   --0.81    0.567
  AFP (positive vs negative)                               3               286              1.049 (0.649--1.697)   0.844                  1.052 (0.648--1.708)   0.837         0.0%           0.524   --0.52   1.000   --0.42    0.745
  Liver cirrhosis (yes vs no)                              3               286              0.976 (0.596--1.600)   0.924                  0.978 (0.595--1.607)   0.930         0.0%           0.618   --0.52   1.000   --0.38    0.769
  Tumor number (multiple vs single)                        3               286              1.542 (0.890--2.670)   0.122                  1.514 (0.592--3.868)   0.387         62.7%          0.069   0.52     1.000   --0.01    0.992
  Tumor encapsulation (incomplete vs complete)             2               200              0.767 (0.416--1.413)   0.394                  0.767 (0.416--1.413)   0.394         0.0%           0.931   1.00     1.000   --        --
  Vascular invasion (yes vs no)                            2               216              2.363 (1.217--4.589)   0.011                  2.349 (0.872--6.332)   0.091         53.7%          0.141   --1.00   1.000   --        --
  TNM stage (III--IV vs I--II)                             3               286              2.796 (1.615--4.841)   \<**0.001**            2.690 (1.540--4.699)   **0.001**     0.0%           0.436   1.57     0.296   0.99      0.502
  **Other digestive system cancers (ESCC, GC, and CRC)**                                                                                                                                                                         
  Age (\>55 vs ≥55)                                        2               318              1.067 (0.679--1.677)   0.778                  1.074 (0.662--1.744)   0.772         11.5%          0.288   1.00     1.000   --        --
  Gender (male vs female)                                  3               414              0.770 (0.495--1.198)   0.246                  0.753 (0.454--1.249)   0.273         13.8%          0.313   --1.57   0.296   --5.71    0.110
  Lymph node metastasis (present vs absent)                3               414              2.374 (1.562--3.608)   \<**0.001**            2.341 (1.478--3.709)   \<**0.001**   14.0%          0.313   --0.52   1.000   --0.99    0.502
  Distant metastasis (present vs absent)                   3               414              3.945 (1.974--7.884)   \<**0.001**            3.964 (1.987--7.906)   \<**0.001**   0.0%           0.722   --1.57   0.296   --20.83   0.031
  Poor/undifferentiated vs Well/moderated                  3               414              1.949 (1.158--3.281)   **0.012**              1.928 (1.139--3.262)   **0.014**     0.0%           0.421   1.57     0.296   16.30     0.039
  Stage (III/IV vs I/II)                                   3               414              2.560 (1.702--3.851)   \<**0.001**            2.515 (1.332--4.746)   **0.004**     55.0%          0.109   0.52     1.000   --0.17    0.892

**Notes:** *p*-value in bold indicates statistical significance. "--" *p*-value cannot be calculated.

**Abbreviations:** TPX2, Xenopus kinesin-like protein 2; HCC, hepatocellular carcinoma; HBsAg, hepatitis B surface antigen; TNM, tumor node and metastasis; ESCC, esophageal squamous cell carcinoma; GC, gastric cancer; CRC, colorectal cancer; AFP, alpha-fetoprotein.
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